Aurobindo Pharma, the sixth largest pharma entity in India with net sales above Rs.12,000 crore, has posted lower consolidated net profit of Rs.404 crore during the fourth quarter ended March 2015 as against Rs.502 crore in the corresponding period of last year. Lower profit is mainly due to higher staff and other costs. Its consolidated net sales, however, improved smartly by 36.3 per cent to Rs.3,144 crore from Rs.2,306 crore. With lower net profit its EPS worked out to Rs.13.84 as against Rs.17.23 in the last period.

The board of directors has recommended liberal bonus issue in the ratio of 1:1 and also recommended third interim dividend of 100 per cent for the year 2014-15 in addition to the interim dividends of 350 per cent, aggregating to 450 per cent.

N Govindarajan, managing director, said, “We are pleased to report another year of strong performance with sustained margins. We believe that the acquired businesses would further enhance the performance going forward.”

For the full year ended March 2015, Aurobindo's consolidated net sales increased by 49.8 per cent to Rs.12,043 crore from Rs.8,038 crore in the previous year. Its formulations sales improved sharply by 77.7 per cent to Rs.9,559 crore from Rs.5,379 crore. Its sales in US increased by 42 per cent to Rs.4,832 crore from Rs.3,403 crore and that in Europe jumped to Rs.3,195 crore from Rs.672 crore. Its sales in RoW moved up by 22.6 per cent to Rs.568 crore from Rs.463 crore.

Though its formulation sales improved, its APIs sales declined by 5.5 per cent to Rs.2,706 crore from Rs.2,864 crore due to lower sales of SSPs and non-betalactam. The sales of SSPs declined by 11.6 per cent to Rs.864 crore from Rs.978 crore and that of non-betalactam by 9.8 per cent to Rs.912 crore from Rs.1,011 crore. Further, its dossier income also declined by 53.3 per cent to Rs.7.7 crore from Rs.16.5 crore in the previous year.

The consolidated net profit improved by 34.4 per cent to Rs.1,576 crore from Rs.1,173 crore and its EPS worked out to Rs.54.05 as against Rs.40.27 in the previous year. EBIDT also improved by 22.6 per cent to Rs.2,645 crore from Rs.2,157 crore as its other income went up to Rs.80.76 crore from Rs.21.56 crore. Forex loss declined to Rs.59.60 crore from Rs.203.06 crore. The company has successfully reduced its interest burden to Rs.84.31 crore from Rs.107.94 crore.

The company filed 40 ANDAs with US FDA during 2014-15 and its cumulative filings reached at 376 ANDAs. It filed 7 DMFs and total filings worked out to 188 DMFs. It filed 236 formulations dossiers. in other key advanced markets like EU, SA and Canada. Cumulative filings of dossiers reached at 2,184. It also filed 159 DMF/COS in other key regulated markets and filed 33 patents in 2014-15.